- Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer. Annals of Thoracic Surgery. 2017 Academic Article GET IT
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
The lancet oncology.
Times cited: 61
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Journal of Thoracic Oncology.
Times cited: 49